Hepatocellular Carcinoma - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Hepatocellular Carcinoma - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 791-page report is available in PDF from $2000.

Hepatocellular Carcinoma - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Hepatocellular Carcinoma - Pipeline Review, H1 2015’, provides an overview of the Hepatocellular Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
Introduction 8
Hepatocellular Carcinoma Overview 9
Therapeutics Development 10
Hepatocellular Carcinoma - Therapeutics under Development by Companies 12
Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 22
Hepatocellular Carcinoma - Pipeline Products Glance 25
Hepatocellular Carcinoma - Products under Development by Companies 28
Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 40
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 42
Hepatocellular Carcinoma - Therapeutics Assessment 152
Drug Profiles 171
Hepatocellular Carcinoma - Recent Pipeline Updates 520
Hepatocellular Carcinoma - Dormant Projects 752
Hepatocellular Carcinoma - Discontinued Products 760
Hepatocellular Carcinoma - Product Development Milestones 763
Appendix 770

For more information open Hepatocellular Carcinoma - Pipeline Review, H1 2015.


Original Article: Hepatocellular Carcinoma - Pipeline Review, H1 2015


More From BioPortfolio on "Hepatocellular Carcinoma - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...